Co-Diagnostics, Inc. (CODX) is a Salt Lake City-based molecular diagnostics company that develops PCR reagents and its Co-Dx PCR testing platform for point-of-care and at-home use, along with vector-control and agricultural tests. Its shares were down 9.84% at $0.2332 in Monday's session, against a prior close of $0.2586. The stock opened at $0.25, touched $0.225 — a new 52-week low — and remained deep in negative territory. No verified news catalyst was published for Monday's decline; the move extends a repricing that followed the company's third-quarter report on Nov. 10 and its Nov. 13 special shareholder meeting.
The core of the bear case is cash. Third-quarter revenue rose to $282,881 from $145,380 a year earlier, and operating expenses fell 12% to $6.25 million, but the company still posted a net loss of $6.31 million, or $1.01 per share. Cash and equivalents stood at just $714,803 on Sept. 30 after $20.7 million of operating cash use in the first nine months of 2026. Management disclosed a subsequent senior secured convertible note financing of roughly $2.1 million, with $1.0 million more available subject to conditions — a sum that buys months, not years, of runway at the current burn rate. None of this was new on Monday, but with no product approved for sale on the Co-Dx PCR platform, the market has continued to discount the equity accordingly.
At the Nov. 13 special meeting, shareholders approved a set of proposals that increases the share count available for future issuance, including warrants for 3.4 million shares and shares underlying the convertible notes, plus a reverse stock split at ratios of no less than 1-for-2 with a cumulative effect capped at 1-for-750. Reverse-split authority typically becomes relevant when a stock trades well below Nasdaq's $1.00 minimum bid, and CODX has traded under that threshold since September. For holders, the combination of authorized share expansion and split authority signals more potential dilution ahead rather than a resolution of the funding gap.
Operationally, the company has two submissions under review: a dual 510(k) and CLIA Waiver by Application for its Flu A/B & RSV test filed with the FDA in August, and the CoSara PCR MTB tuberculosis test submitted to India's CDSCO, which showed roughly 97.3% sensitivity and 96% specificity in clinical study. Both are potentially meaningful for a company with a market value of about $2.5 million, but neither generates revenue today, and management offered no guidance on the Nov. 10 call, which consisted of prepared remarks only with no question-and-answer session.
Turnover was not heavy: roughly 80,000 shares changed hands in the first 45 minutes, about a quarter of the stock's recent full-day average near 340,000 shares, suggesting thin liquidity rather than a single large seller. The decline came alongside broad weakness, with the S&P 500-tracking SPDR fund down about 1.1% and major biotech exchange-traded funds off 0.7% to 1.3%, though CODX's move was far larger than any sector benchmark. Technically, the stock lost the $0.2450 low from Nov. 13 and trades roughly 70% below its 50-day moving average near $0.80 and about 89% below its 200-day average near $2.07, with momentum deeply oversold.
On a scale where 0 means no meaningful news and a move entirely normal for the stock, and 100 means transformative news and an extreme, rare price move, Co-Diagnostics scores 28 out of 100. The verified news is material for a company this small — a $6.3 million quarterly loss, $714,803 of cash, a new convertible note and freshly approved share and reverse-split authorities — but it was disclosed between Nov. 10 and Nov. 13 and is largely reflected in the price already.
The decline itself was about 1.9 times the stock's typical daily move of roughly 5.1%, and moves of this magnitude have occurred 10 times in the past 69 sessions. Moderate news and a modest anomaly combine into a low-to-mid score.
The next scheduled financial update is not expected until roughly late March 2027, leaving investors to trade headlines in the interim. Near-term catalysts include a CDSCO decision on the TB test, which the company has indicated could precede a commercial launch in India before the end of 2026, and continued FDA review of the respiratory panel. Management's presence at global tuberculosis events in Rio de Janeiro this week may generate updates. The principal risks are a dilutive equity raise, continued cash burn, potential Nasdaq listing pressure and the possibility that either regulatory submission is delayed or rejected. Analysts remain sparsely covering the name, and expectations should be treated cautiously given the absence of formal guidance.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Each bot differs by strategy, timeframe, performance metrics and the symbols it trades, so the lineup rotates as market conditions change. For traders navigating volatile micro-caps like this one, reviewing the current leaders can help frame risk and timing decisions. Explore the page to see which automated strategies are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where CODX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CODX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA
Industry MedicalNursingServices